APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ), made an announcement that approval has been received from the U.S. Food and Drug Administration (FDA) for the marketing of Chlorothiazide Sodium for Injection, USP.

This injectable form of Chlorothiazide Sodium is expected to be launched by APP in the fourth quarter of 2009.

From News-Medical.Net:

Chlorothiazide Sodium for Injection, USP is therapeutically equivalent to the reference-listed drug Diuril®, which is marketed by Lundbeck Pharmaceuticals. According to 2008 IMS data, sales of this product in the United States were approximately $51 million1. Chlorothiazide is a diuretic used to treat high blood pressure (hypertension), as well as fluid retention in people with congestive heart failure, cirrhosis of the liver, kidney disorders, or edema caused by taking steroids or estrogen.

Thomas H. Silberg, president and chief executive officer of APP Pharmaceuticals, said that the present stream of ANDA approvals reinforces commitment of APP when it comes to offering a consistently expanding portfolio of products to the customers and the patients.